Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in treating various cancers. They are monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death-ligand 1 (PD-L1). However, activation of t...
| Published in: | Current Oncology Vol. 29; no. 4; pp. 2871 - 2887 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Published: |
MDPI
Apr2022
|
| Online Access: | View this record in EBSCOhost |